OspA lipoprotein of Borrelia burgdorferi is a mucosal immunogen and adjuvant. (Q52042585)

20 April 2018

title

OspA lipoprotein of Borrelia burgdorferi is a mucosal immunogen and adjuvant. (English)

1 reference

20 April 2018

0 references

1 reference

Erdile LF

1

1 reference

20 April 2018

Guy B

series ordinal

2

1 reference

20 April 2018

language of work or name

English

0 references

publication date

1 June 1997

1 reference

20 April 2018

number of pages

9

1 reference

inferred from page(s)

published in

Vaccine

1 reference

20 April 2018

volume

15

1 reference

20 April 2018

issue

9

1 reference

20 April 2018

page(s)

988-996

1 reference

20 April 2018

Mucosal immunity to infection with implications for vaccine development

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900295-2

7 January 2021

Immunogenic integral membrane proteins of Borrelia burgdorferi are lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900295-2

7 January 2021

Incomplete protection of hamsters vaccinated with unlipidated OspA from Borrelia burgdorferi infection is associated with low levels of antibody to an epitope defined by mAb LA-2

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900295-2

7 January 2021

Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900295-2

7 January 2021

Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) lyme vaccines in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900295-2

7 January 2021

Safety and Immunogenicity of an Outer Surface Protein A Vaccine in Subjects with Previous Lyme Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900295-2

7 January 2021

Specific antibodies elicited by antigen covalently linked to a synthetic adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900295-2

7 January 2021

In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900295-2

7 January 2021

Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900295-2

7 January 2021

Oral administration of an antigenic synthetic lipopeptide (MAP-P3C) evokes salivary antibodies and systemic humoral and cellular responses.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900295-2

7 January 2021

Lipopeptide derivatives of bacterial lipoprotein constitute potent immune adjuvants combined with or covalently coupled to antigen or hapten

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900295-2

7 January 2021

Enhancement of protection against Salmonella infection in mice mediated by a synthetic lipopeptide analogue of bacterial lipoprotein in S. typhimurium vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900295-2

7 January 2021

Borrelia burgdorferi outer surface lipoproteins OspA and OspB possess B-cell mitogenic and cytokine-stimulatory properties

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900295-2

7 January 2021

Normal human B lymphocytes and mononuclear cells respond to the mitogenic and cytokine-stimulatory activities of Borrelia burgdorferi and its lipoprotein OspA.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900295-2

7 January 2021

Activation of bone marrow-derived mouse macrophages by bacterial lipopeptide: cytokine production, phagocytosis and Ia expression.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900295-2

7 January 2021

Enhancing effect of cholera toxin on interleukin-6 secretion by IEC-6 intestinal epithelial cells: mode of action and augmenting effect of inflammatory cytokines.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900295-2

7 January 2021

Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900295-2

7 January 2021

Development of a mouse model of Helicobacter pylori infection that mimics human disease

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900295-2

7 January 2021

Outer surface protein A (OspA) from the Lyme disease spirochete, Borrelia burgdorferi: high level expression and purification of a soluble recombinant form of OspA.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900295-2

7 January 2021

The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900295-2

7 January 2021

Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900295-2

7 January 2021

A fusion plasmid for the synthesis of lipopeptide-antigen chimeras in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900295-2

7 January 2021

10.1016/S0264-410X(96)00295-2

Identifiers

DOI

1 reference

20 April 2018

PubMed ID

9261945

1 reference

20 April 2018